PRISM BioLab
PRISM BioLab, founded in 2006 by a team of scientists, focuses on developing novel drugs based on its proprietary peptide-mimetic small-molecule technology. Over more than a decade of R&D, the company has advanced a clinical pipeline and generated multiple potential seed compounds. In 2026, PRISM BioLab has gained attention through a major AI partnership and encouraging clinical trial results from its oncology pipeline.
PRISM BioLab gained attention in 2026 through a strategic AI partnership, positive clinical data, and continued advancement of its peptide-mimetic drug discovery platform. In March, the company partnered with Receptor.AI to combine its proprietary PepMetics technology with AI-driven drug design to develop oral small molecules against challenging metabolic targets, including obesity. In January, positive Phase 1 results for E7386, an oncology candidate developed with Eisai, were published in ESMO Open. The company also highlighted its peptide-mimetic technology at the LINK-J Drug Discovery Frontier 2026 symposium in July. Its platform aims to address previously “undruggable” targets and enable the development of orally available therapies.
“PRISM BioLab is advancing next-generation drug discovery by combining peptide-mimetic chemistry with AI to tackle previously undruggable targets and deliver novel oral therapies.”
Eribulin mesylate (E-7386)
Mechanism of Action: Receptor protein-tyrosine kinase modulators; Transcription factor modulators; Tubulin polymerisation inhibitors Drug Class: Small molecules Originator: Eisai Co Ltd Indication: Solid tumours
E7386, an oral investigational cancer therapy, is gaining attention following Phase 1 results published in ESMO Open, which demonstrated a manageable safety profile and early signs of anti-tumor activity. The CBP/β-catenin inhibitor targets the Wnt signaling pathway and has a recommended monotherapy dose of 120 mg twice daily. Partial responses were observed in patients with certain small bowel and desmoid tumors. Ongoing studies are also evaluating E7386 in combination with lenvatinib for advanced solid tumors, including endometrial cancer.
PRISM BioLab Revenue Trends (2020–2025)
PRISM BioLab’s revenue remained relatively modest and volatile over 2020–2025, reflecting the company’s development-stage business model. Revenue declined sharply from $6 million in 2020 to $0.54 million in 2021, primarily due to fluctuations in collaboration and licensing-related income. It recovered to $5 million in 2022 before gradually declining to $2 million in 2024, likely reflecting the timing of research collaborations and milestone-related payments. Revenue rebounded to approximately $4.7 million in 2025, supported by renewed business activity and partnerships. Overall, the fluctuations largely reflect the lumpy nature of revenue from collaborations, licensing, and milestone payments, rather than a conventional product-sales cycle.
"PRISM BioLab’s revenue volatility reflects the milestone-driven nature of its collaborations, with a strong rebound to $4.7 million in 2025."
Six-year market revenue of PRISM BioLab (2020- 2025)
Fig 13: Market revenue of PRISM BioLab
PRISM BioLab Clinical Development and Discovery Pipeline
PRISM BioLab leverages its proprietary PepMetics® platform to discover and develop novel therapeutics targeting challenging protein-protein interactions (PPIs). Compounds generated through the platform are licensed to pharmaceutical partners, who are responsible for advancing nonclinical and clinical development.
The company's most advanced programs, E7386 and PRI-724 (OP-724), target the CBP/β-catenin signaling pathway, a key regulator of cancer progression. Both oncology candidates have progressed to Phase 2 clinical development, demonstrating the potential of the PepMetics® platform to generate clinically relevant therapies.
Beyond partnered clinical assets, PRISM BioLab maintains a robust internal pipeline focused on oncology, fibrosis, autoimmune diseases, rare diseases, and metabolic disorders. The lead program, FEP, targeting the eIF4E/eIF4G interaction, is currently in lead optimization, while multiple additional programs targeting transcription factors, cyclin-dependent kinases (CDKs), GPCRs, and transporters are progressing through the Hit-to-Lead stage, supporting a sustainable pipeline of future licensing opportunities.
